Search

The edition closes with more than 2,400 attendees from over 1,000 organizations across 34 countries. BIOSPAIN 2025 brought together 140 investors representing 76 national and international investment

Artificial intelligence enables the analysis of millions of biological data points to identify optimal solutions, while automation facilitates the transfer of results from the lab to industry.

The Spanish biotech ecosystem, despite its progress in investment, R&D, business creation, and international visibility, still needs to strengthen public-private collaborations and take greater

The upcoming Biotech Act and the European Pharmaceutical Strategy are crucial for the development of advanced therapies in Europe, as they aim to create a more agile and predictable regulatory

We spoke with Gonzalo de Miquel, Vice President of Global Clinical Development at Alexion Pharmaceuticals (AstraZeneca Rare Disease), Gold Sponsor of BIOSPAIN 2025.

From October 7–9, the Fira de Barcelona will host the 12th edition of BIOSPAIN, organized by AseBio and Biocat, in collaboration with the Government of Catalonia and the Barcelona City Council.

AseBio presents at BIOSPAIN 2025 the report “The new geopolitics of biotechnology”, which analyzes the global race of the sector and Spain’s strategic role in the new balance of power among the United

Carlos Mackintosh, Senior Principal Scientist, Translational IPS, Bristol Myers Squibb – CITRE and Silver Sponsor of BIOSPAIN, highlights the strategic role of the Center for Innovation and

Jose Terencio, Senior Vice President, Discovery at Grifols and Gold Sponsor of BIOSPAIN, reaffirms the company’s commitment to open innovation as a driving force to diversify its pipeline, accelerate

Pilar Gil, coCEO of SID and Platinum Sponsor of BIOSPAIN 2025, highlights the importance of having flexible infrastructures and collaborative ecosystems as key elements for the development and growth

The start-up Dan*na (Artificial Nature S.L.), based at the Barcelona Science Park, has validated the industrial scale-up of its innovative bioplastic PLH, a patented and biodegradable copolyester that

Albert Font, CEO of Leanbio and Platinum Sponsor of BIOSPAIN 2025, analyzes the strategic role of innovation, agility, and collaboration in the development and manufacturing of biological products.

Oryzon Genomics has strengthened its patent portfolio with the European grant of protection for iadademstat in combination with PD1/PD-L1 inhibitors in the treatment of cancer, including small-cell